BioNTech and BMS Report Promising Phase 2 Results for TNBC Treatment

BioNTech SE ( (BNTX) ) has issued an announcement.

On December 9, 2025, BioNTech SE and Bristol Myers Squibb announced interim results from a global Phase 2 trial evaluating pumitamig, a bispecific antibody, in combination with chemotherapy for treating locally advanced/metastatic triple-negative breast cancer (TNBC). The trial showed promising anti-tumor activity, with a confirmed objective response rate of 61.5% and a disease control rate of 92.3%, irrespective of PD-L1 expression levels. These findings highlight the potential of pumitamig to address the unmet needs in TNBC treatment, especially for patients with PD-L1 low or negative tumors, and support its further investigation in the Phase 3 ROSETTA BREAST-01 trial.

The most recent analyst rating on (BNTX) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

Spark’s Take on BNTX Stock

According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.

BioNTech’s overall stock score reflects a challenging financial performance with recent losses, offset by a strong balance sheet and strategic advancements in oncology. Technical indicators suggest a neutral trend, while valuation remains unattractive due to negative earnings. The earnings call provided positive guidance, but regulatory delays and financial losses remain concerns.

To see Spark’s full report on BNTX stock, click here.

More about BioNTech SE

BioNTech SE is a biotechnology company known for its work in developing innovative cancer therapies and vaccines. The company focuses on leveraging the body’s immune system to fight cancer and infectious diseases, with a significant emphasis on mRNA technology.

Average Trading Volume: 1,015,049

Technical Sentiment Signal: Strong Sell

Current Market Cap: $23.14B

Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.